Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia J Zettler

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
EMBO Molecular Medicine|July 24, 2015
Compassionate use of experimental therapies: who should decide?Patricia J Zettler
Journal of Law and the Biosciences|October 25, 2016
Regulating drug promotion to promote the public health: a response to Bennett et alPatricia J Zettler
Drug Discovery Today|November 6, 2019
A special exception for CBD in foods and supplements?Patricia J Zettler, Erika Lietzan
The New England Journal of Medicine|January 12, 2022
State Restrictions on Mifepristone Access - The Case for Federal PreemptionPatricia J Zettler, Ameet Sarpatwari
American Journal of Public Health|September 2, 2021
Broader Implications of Eliminating FDA Jurisdiction Over Execution DrugsPatricia J Zettler, Seema K Shah
JAMA Internal Medicine|September 30, 2014
The strange allure of state "right-to-try" lawsPatricia J Zettler, Henry T Greely
Cancer|November 3, 2018
Food and drug administration's regulatory shift on direct-to-consumer genetic tests for cancer riskY Tony Yang, Patricia J Zettler
JAMA|April 28, 2025
The FDA's Crisis Is Everyone's CrisisPatricia J Zettler, Nathan G Cortez
The American Journal of Managed Care|February 1, 2017
The challenge of paying for cost-effective curesPatricia J Zettler, Erin C Fuse Brown
Clinical Pharmacology and Therapeutics|December 23, 2017
Prevalence of Publicly Available Expanded Access PoliciesEmily Jung, Patricia J Zettler, Aaron S Kesselheim
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
EMBO Molecular Medicine|July 24, 2015
Compassionate use of experimental therapies: who should decide?Patricia J Zettler
Journal of Law and the Biosciences|October 25, 2016
Regulating drug promotion to promote the public health: a response to Bennett et alPatricia J Zettler
Drug Discovery Today|November 6, 2019
A special exception for CBD in foods and supplements?Patricia J Zettler, Erika Lietzan
The New England Journal of Medicine|January 12, 2022
State Restrictions on Mifepristone Access - The Case for Federal PreemptionPatricia J Zettler, Ameet Sarpatwari
American Journal of Public Health|September 2, 2021
Broader Implications of Eliminating FDA Jurisdiction Over Execution DrugsPatricia J Zettler, Seema K Shah
JAMA Internal Medicine|September 30, 2014
The strange allure of state "right-to-try" lawsPatricia J Zettler, Henry T Greely
Cancer|November 3, 2018
Food and drug administration's regulatory shift on direct-to-consumer genetic tests for cancer riskY Tony Yang, Patricia J Zettler
JAMA|April 28, 2025
The FDA's Crisis Is Everyone's CrisisPatricia J Zettler, Nathan G Cortez
The American Journal of Managed Care|February 1, 2017
The challenge of paying for cost-effective curesPatricia J Zettler, Erin C Fuse Brown
Clinical Pharmacology and Therapeutics|December 23, 2017
Prevalence of Publicly Available Expanded Access PoliciesEmily Jung, Patricia J Zettler, Aaron S Kesselheim
Pageof 6